Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Safeguarding America's Pharmaceuticals Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Safeguarding America's Pharmaceuticals Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2020 · fourth_quarter · Q4
Raise awareness of synthetic CBD for research and hemp legislation; Advocate for inclusion of synthetic CBD in Farm Bill or other legislation
Raise awareness of synthetic CBD for research and hemp legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| STIEFEL LABORATORIES, INC. |
| 8 |
| 2008–2009 |
| PHOENIX SCIENTIFIC INC | 7 | 2003–2006 |
| CONCORDIA HEALTHCARE CORP. | 5 | 2015–2016 |
| CONCORDIA PHARMACEUTICALS INC. | 5 | 2014–2015 |
| IDM PHARMA INC. | 5 | 2007 |
| WOCKHARDT LTD | 5 | 2014 |
| ROHO GROUP | 4 | 2004–2006 |
| TONIX PHARMACEUTICALS HOLDING CORP. | 4 | 2017 |
| CYGENE INC | 3 | 2001–2003 |
| ELGE INC. | 3 | 2008 |
| GENLANTIS (DIVISION OF GENE THERAPY SYSTEMS INC ) | 3 | 2009–2010 |
| TMO RENEWABLES LTD | 3 | 2007–2008 |
| WARNEX | 3 | 2006–2007 |
| AL-NAJAT | 2 | 2003 |
| CROSS VETPHARM | 2 | 2004 |
| NEUROTECHNOLOGY INDUSTRY ORGANIZATION (NIO) | 2 | 2007 |
| PATEL DR SATISH P | 2 | 2001 |
| PERRIGO | 2 | 2003 |
| PLIVA INC | 2 | 2001–2003 |
| SHEFFIELD PHARMACEUTICALS | 2 | 2008 |
| ADPROTECH PLC | 1 | 2001 |
| DAIICHI SANKYO | 1 | 2007 |
| GENAISSANCE PHARMACEUTICALS | 1 | 2001 |
| GRADIPORE INC | 1 | 2001 |
| TURING PHARMACEUTICALS | 1 | 2015 |
| UNIVERSITY OF PITTSBURGH MEDICAL CENTER | 1 | 2006 |
| WALGREEN CO | 1 | 2008 |
Safeguarding America's Pharmaceuticals Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Safeguarding America's Pharmaceuticals Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Safeguarding America's Pharmaceuticals Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Safeguarding America's Pharmaceuticals Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Antibiotic Development to Advance Patient Treatment Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Antibiotic Development to Advance Patient Treatment Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Antibiotic Development to Advance Patient Treatment Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Antibiotic Development to Advance Patient Treatment Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Antibiotic Development to Advance Patient Treatment Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Antibiotic Development to Advance Patient Treatment Act of 2013
Client: WOCKHARDT LTD · Firm: BUCHANAN INGERSOLL & ROONEY PC
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
2020 · third_quarter · Q3
Raise awareness of synthetic CBD for research and hemp legislation
Raise awareness of synthetic CBD for research and hemp legislation; Advocate for inclusion of synthetic CBD in Farm Bill or other legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2020 · second_quarter · Q2
Raise awareness of synthetic CBD for research and hemp legislation
Raise awareness of synthetic CBD for research and hemp legislation; Advocate for inclusion of synthetic CBD in Farm Bill or other legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2020 · first_quarter · Q1
Raise awareness of synthetic CBD for research and hemp legislation
Raise awareness of synthetic CBD for research and hemp legislation; Advocate for inclusion of synthetic CBD in Farm Bill or other legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2019 · fourth_quarter · Q4
Raise awareness of synthetic CBD for research and hemp legislation
Raise awareness of synthetic CBD for research and hemp legislation; Advocate for inclusion of synthetic CBD in Farm Bill or other legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2019 · third_quarter · Q3
Raise awareness of synthetic CBD for research and hemp legislation
Raise awareness of synthetic CBD for research and hemp legislation; Advocate for inclusion of synthetic CBD in Farm Bill or other legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2019 · second_quarter · Q2
Raise awareness of synthetic CBD for research and hemp legislation; Advocate for inclusion of synthetic CBD in Farm Bill or other legislation
Raise awareness of synthetic CBD for research and hemp legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2019 · first_quarter · Q1
Raise awareness of synthetic CBD for research and hemp legislation
Raise awareness of synthetic CBD for research and hemp legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2018 · fourth_quarter · Q4
DEA Approval of clinical studies
DEA Approval of clinical studies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2018 · third_quarter · Q3
DEA Approval of clinical studies
DEA Approval of clinical studies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS HOLDING CORP. via BUCHANAN INGERSOLL & ROONEY PC
2017 · third_quarter · Q3
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
TONIX PHARMACEUTICALS HOLDING CORP. via BUCHANAN INGERSOLL & ROONEY PC
2017 · second_quarter · Q2
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
TONIX PHARMACEUTICALS HOLDING CORP. via BUCHANAN INGERSOLL & ROONEY PC
2017 · first_quarter · Q1
Federal funding related to clinical trials for military PTSD
Federal funding related to clinical trials for military PTSD
Federal funding related to clinical trials for military PTSD
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2017 · first_quarter · Q1
FDA related Application issues; pricing of prescription drugs
FDA related Application issues; pricing of prescription drugs
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS HOLDING CORP. via BUCHANAN INGERSOLL & ROONEY PC
2017 · first_quarter · RR
Federal funding related to clinical trials for military PTSD
Federal funding related to clinical trials for military PTSD
Federal funding related to clinical trials for military PTSD
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2016 · fourth_quarter · Q4
FDA related Application issues; pricing of prescription drugs
FDA related Application issues; pricing of prescription drugs
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA HEALTHCARE CORP. via BUCHANAN INGERSOLL & ROONEY PC
2016 · third_quarter · Q3
Strategy development and implementation of federal government relations initiatives regarding PDUFA/GDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation. FDA process of enforcement of illegally manufactured drugs; pricing of prescription drugs
Strategy development and implementation of federal government relations initiatives regarding PDUFA/GDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation. FDA process of enforcement of illegally manufactured drugs; pricing of prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2016 · third_quarter · Q3
FDA related Application issues; pricing of prescription drugs
FDA related Application issues; pricing of prescription drugs
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA HEALTHCARE CORP. via BUCHANAN INGERSOLL & ROONEY PC
2016 · second_quarter · Q2
Strategy development and implementation of federal government relations initiatives regarding PDUFA/GDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation. FDA process of enforcement of illegally manufactured drugs; pricing of prescription drugs
Strategy development and implementation of federal government relations initiatives regarding PDUFA/GDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation. FDA process of enforcement of illegally manufactured drugs; pricing of prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2016 · second_quarter · Q2
FDA related Application issues; pricing of prescription drugs
FDA related Application issues; pricing of prescription drugs
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2016 · first_quarter · Q1
FDA related Application issues; pricing of prescription drugs
FDA related Application issues; pricing of prescription drugs
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA HEALTHCARE CORP. via BUCHANAN INGERSOLL & ROONEY PC
2016 · first_quarter · Q1
Strategy development and implementation of federal government relations initiatives regarding PDUFA/GDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation. FDA process of enforcement of illegally manufactured drugs; pricing of prescription drugs
Strategy development and implementation of federal government relations initiatives regarding PDUFA/GDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation. FDA process of enforcement of illegally manufactured drugs; pricing of prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA HEALTHCARE CORP. via BUCHANAN INGERSOLL & ROONEY PC
2015 · fourth_quarter · Q4
Strategy development and implementation of federal government relations initiatives regarding PDUFA/GDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation.
Strategy development and implementation of federal government relations initiatives regarding PDUFA/GDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA HEALTHCARE CORP. via BUCHANAN INGERSOLL & ROONEY PC
2015 · fourth_quarter · RR
Strategy development and implementation of the company's federal government relations initiatives.
Strategy development and implementation of the company's federal government relations initiatives.
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2015 · third_quarter · Q3
DEA/FDA clinical study compliance; Congressional and DEA outreach
DEA/FDA clinical study compliance; Congressional and DEA outreach
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2015 · third_quarter · Q3
Strategy development and implementation of federal government relations initiatives regarding PDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation.
Strategy development and implementation of federal government relations initiatives regarding PDUFA reauthorization and generic pricing, Average Manufacturer Price proposed regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TURING PHARMACEUTICALS via BUCHANAN INGERSOLL & ROONEY PC
2015 · third_quarter · RR
Strategy development and implementation of the companys federal government relations initiatives
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2015 · second_quarter · Q2
DEA/FDA clinical study compliance; Congressional and DEA outreach
DEA/FDA clinical study compliance; Congressional and DEA outreach
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2015 · second_quarter · Q2
Strategy development and implementation of federal government relations initiatives regarding the importing of Active Pharmaceutical Ingredients into the United States.
Strategy development and implementation of federal government relations initiatives regarding the importing of Active Pharmaceutical Ingredients into the United States.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2015 · first_quarter · Q1
DEA/FDA clinical study compliance; Congressional and DEA outreach
DEA/FDA clinical study compliance; Congressional and DEA outreach
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2015 · first_quarter · Q1
Strategy development and implementation of federal government relations initiatives regarding the importing of Active Pharmaceutical Ingredients into the United States.
Strategy development and implementation of federal government relations initiatives regarding the importing of Active Pharmaceutical Ingredients into the United States.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYNERBA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2015 · first_quarter · RR
DEA/FDA clinical study compliance
DEA/FDA clinical study compliance
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2014 · first_quarter · 1A
Legislative issues relating to United States Food & Drug Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WOCKHARDT LTD via BUCHANAN INGERSOLL & ROONEY PC
2014 · fourth_quarter · Q4
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2014 · fourth_quarter · Q4
Strategy development and implementation of federal government relations initiatives
Strategy development and implementation of federal government relations initiatives
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONCORDIA PHARMACEUTICALS, INC. via BUCHANAN INGERSOLL & ROONEY PC
2014 · fourth_quarter · RR
Strategy development and implementation of federal government relations initiatives.
Strategy development and implementation of federal government relations initiatives.
WOCKHARDT LTD via BUCHANAN INGERSOLL & ROONEY PC
2014 · third_quarter · Q3
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WOCKHARDT LTD via BUCHANAN INGERSOLL & ROONEY PC
2014 · second_quarter · Q2
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WOCKHARDT LTD via BUCHANAN INGERSOLL & ROONEY PC
2014 · first_quarter · Q1
Strategy development and implementation of federal government relations initiatives
Strategy development and implementation of federal government relations initiatives
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2014 · first_quarter · Q1
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WOCKHARDT LTD via BUCHANAN INGERSOLL & ROONEY PC
2014 · first_quarter · RR
Strategy development and implementation of federal government relations initiatives
Strategy development and implementation of federal government relations initiatives
FERRING PHARMACEUTICALS - USA via BUCHANAN INGERSOLL & ROONEY PC
2013 · fourth_quarter · 4A
Health Care and pharmaceutical issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS - USA via BUCHANAN INGERSOLL & ROONEY PC
2013 · fourth_quarter · Q4
Health Care and pharmaceutical issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2013 · fourth_quarter · Q4
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2013 · fourth_quarter · Q4
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2013 · third_quarter · Q3
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS - USA via BUCHANAN INGERSOLL & ROONEY PC
2013 · third_quarter · Q3
Health Care and pharmaceutical issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2013 · third_quarter · Q3
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2013 · second_quarter · Q2
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS - USA via BUCHANAN INGERSOLL & ROONEY PC
2013 · second_quarter · Q2
Health Care and pharmaceutical issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2013 · second_quarter · Q2
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2013 · first_quarter · Q1
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS - USA via BUCHANAN INGERSOLL & ROONEY PC
2013 · first_quarter · Q1
Health Care and pharmaceutical issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2013 · first_quarter · Q1
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS - USA via BUCHANAN INGERSOLL & ROONEY PC
2013 · first_quarter · RA
Health care and pharmaceutical issues.
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2012 · fourth_quarter · Q4
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2012 · fourth_quarter · Q4
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2012 · third_quarter · Q3
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2012 · third_quarter · Q3
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2012 · second_quarter · Q2
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2012 · second_quarter · Q2
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2012 · first_quarter · Q1
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2012 · first_quarter · Q1
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2011 · fourth_quarter · Q4
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
DESTON THERAPEUTICS, LLC via BUCHANAN INGERSOLL & ROONEY PC
2011 · fourth_quarter · 4T
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2011 · fourth_quarter · Q4
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2011 · third_quarter · Q3
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
DESTON THERAPEUTICS, LLC via BUCHANAN INGERSOLL & ROONEY PC
2011 · third_quarter · Q3
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2011 · third_quarter · Q3
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DESTON THERAPEUTICS, LLC via BUCHANAN INGERSOLL & ROONEY PC
2011 · second_quarter · Q2
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2011 · second_quarter · Q2
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2011 · second_quarter · Q2
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DESTON THERAPEUTICS, LLC via BUCHANAN INGERSOLL & ROONEY PC
2011 · first_quarter · Q1
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2011 · first_quarter · Q1
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2011 · first_quarter · Q1
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2010 · fourth_quarter · Q4
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2010 · fourth_quarter · Q4
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
DESTON THERAPEUTICS, LLC via BUCHANAN INGERSOLL & ROONEY PC
2010 · fourth_quarter · Q4
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DESTON THERAPEUTICS, LLC via BUCHANAN INGERSOLL & ROONEY PC
2010 · third_quarter · Q3
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2010 · third_quarter · Q3
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2010 · third_quarter · Q3
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2010 · second_quarter · Q2
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2010 · second_quarter · Q2
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
DESTON THERAPEUTICS, LLC via BUCHANAN INGERSOLL & ROONEY PC
2010 · second_quarter · Q2
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DESTON THERAPEUTICS, LLC via BUCHANAN INGERSOLL & ROONEY PC
2010 · second_quarter · RR
Health care and pharmaceutical issues within the US House and US Senate.
GENLANTIS (DIVISION OF GENE THERAPY SYSTEMS INC ) via BUCHANAN INGERSOLL & ROONEY PC
2010 · first_quarter · 1T
Appropriations funding for Tuberculosis research and diagnostic testing initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2010 · first_quarter · Q1
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2010 · first_quarter · Q1
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STIEFEL LABORATORIES, INC. via BUCHANAN INGERSOLL & ROONEY PC
2009 · fourth_quarter · 4@
Patent issues and health care reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2009 · fourth_quarter · Q4
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
STIEFEL LABORATORIES, INC. via BUCHANAN INGERSOLL & ROONEY PC
2009 · fourth_quarter · Q4
Patent issues and health care reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2009 · fourth_quarter · Q4
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENLANTIS (DIVISION OF GENE THERAPY SYSTEMS INC ) via BUCHANAN INGERSOLL & ROONEY PC
2009 · fourth_quarter · Q4
Appropriations funding for Tuberculosis research and diagnostic testing initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENLANTIS (DIVISION OF GENE THERAPY SYSTEMS INC ) via BUCHANAN INGERSOLL & ROONEY PC
2009 · fourth_quarter · RR
Appropriations funding for Tuberculosis research and diagnostic testing initiatives
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2009 · third_quarter · Q3
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
STIEFEL LABORATORIES, INC. via BUCHANAN INGERSOLL & ROONEY PC
2009 · third_quarter · Q3
Patent issues and health care reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2009 · third_quarter · Q3
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STIEFEL LABORATORIES, INC. via BUCHANAN INGERSOLL & ROONEY PC
2009 · second_quarter · Q2
Patent issues and health care reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERIC ANIMAL DRUG ALLIANCE via BUCHANAN INGERSOLL & ROONEY PC
2009 · second_quarter · Q2
Legislative issues relating to United States Food & Drug Administration.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRECKENRIDGE PHARMACEUTICAL INC via BUCHANAN INGERSOLL & ROONEY PC
2009 · second_quarter · Q2
Health care and pharmaceutical issues within the US House and US Senate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Federal funding related to clinical trials for military PTSD
Federal funding related to clinical trials for military PTSD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Federal funding related to clinical trials for military PTSD